Insider Selling: Aimmune Therapeutics Inc (AIMT) CFO Sells 10,000 Shares of Stock
Aimmune Therapeutics Inc (NASDAQ:AIMT) CFO Warren L. Desouza sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 21st. The shares were sold at an average price of $22.95, for a total transaction of $229,500.00. Following the transaction, the chief financial officer now directly owns 30,681 shares in the company, valued at $704,128.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Aimmune Therapeutics Inc (NASDAQ:AIMT) traded down 0.51% during trading on Thursday, hitting $19.65. 173,592 shares of the stock traded hands. Aimmune Therapeutics Inc has a 52-week low of $9.77 and a 52-week high of $27.31. The company’s market cap is $987.39 million. The firm has a 50-day moving average price of $21.35 and a 200 day moving average price of $20.43.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Wednesday, March 15th. The biotechnology company reported ($0.55) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by $0.08. On average, equities analysts expect that Aimmune Therapeutics Inc will post ($2.80) EPS for the current year.
Hedge funds have recently modified their holdings of the company. Daiwa SB Investments Ltd. purchased a new stake in shares of Aimmune Therapeutics during the first quarter valued at approximately $132,000. Franklin Street Advisors Inc. NC purchased a new stake in shares of Aimmune Therapeutics during the first quarter valued at approximately $450,000. TD Asset Management Inc. boosted its stake in shares of Aimmune Therapeutics by 136.7% in the third quarter. TD Asset Management Inc. now owns 31,478 shares of the biotechnology company’s stock valued at $472,000 after buying an additional 18,178 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in shares of Aimmune Therapeutics during the third quarter valued at approximately $579,000. Finally, Wells Fargo & Company MN boosted its stake in shares of Aimmune Therapeutics by 6.7% in the third quarter. Wells Fargo & Company MN now owns 54,933 shares of the biotechnology company’s stock valued at $824,000 after buying an additional 3,454 shares during the last quarter. Hedge funds and other institutional investors own 61.61% of the company’s stock.
AIMT has been the topic of a number of recent analyst reports. Zacks Investment Research lowered shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, March 20th. Piper Jaffray Companies raised their price target on shares of Aimmune Therapeutics to $40.00 and gave the company an “overweight” rating in a research report on Saturday, March 11th. Finally, Wedbush reissued an “outperform” rating and set a $42.00 price target on shares of Aimmune Therapeutics in a research report on Friday, February 17th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $33.60.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Stock Ratings for Aimmune Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc and related stocks with our FREE daily email newsletter.